<DOC>
	<DOC>NCT00076206</DOC>
	<brief_summary>The primary objective of this study is to compare the therapeutic response and safety of 3 oral dose levels of CCI-779, with placebo in subjects with active rheumatoid arthritis (RA) who have been receiving stable doses of methotrexate (MTX) for at least 8 weeks.</brief_summary>
	<brief_title>Study Evaluating CCI-779 in Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Meet American College of Rheumatology (ACR) criteria for RA Have active RA consisting of ≥ 6 swollen and ≥ 6 painful joints ACR functional class IIII Exclusion Criteria At screening the subject's prior medications are reviewed. (Prior history of diseasemodifying antirheumatic drug (DMARD) use is recorded, including the start and stop dates of the most recently taken DMARDs) Significant concurrent medical diseases Abnormal chest radiograph, including findings consistent with interstitial pneumonitis, granulomatous disease, or pleural effusion and/or infiltration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>